MedPath

Co Q10 and Semen parameter

Phase 2
Conditions
Male Infertility.
Male infertility
Registration Number
IRCT138706031079N1
Lead Sponsor
Avicenna Research Institute; Tehran Medical Sciences University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
Male
Target Recruitment
60
Inclusion Criteria

Inclusion : idiopathic oligoasthenoteratospermia, normal profile for hormones, normal genital anatomy

Exclusion: major infection in genital organ, treatment for systemic disease during the last three months of inclusion, surgery background on genitalia, exposure to chemicals ,solvents or heavy metals, supplementation therapy in last three months of inclusion

Exclusion Criteria

Not provided

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Semen analysis. Timepoint: 45 days , 90days. Method of measurement: HPLC, flourometry , spectrophotometry, ELIZA.;Sperm Isoprostan concentration. Timepoint: 45 days , 90days. Method of measurement: ELIZA.;Activity of seminal plasma catalase. Timepoint: 45 days , 90days. Method of measurement: spectrophotometry.;Activity of seminal plasma superoxide dysmutase. Timepoint: 45 days , 90days. Method of measurement: spectrophotometry.;Seminal plasma ubiquinone concentration. Timepoint: 45 days , 90days. Method of measurement: HPLC.;DNA fregmentation. Timepoint: 45 days , 90days. Method of measurement: Flowcytometry.
Secondary Outcome Measures
NameTimeMethod
Seminal plasma gluthation reductase. Timepoint: 45 days, 90 days. Method of measurement: spectrophotometry.;Total Antioxidant Capacity(TAC). Timepoint: 45 days, 90 days. Method of measurement: spectrophotometry.;Seminal plasma Coenzyme Q10. Timepoint: 45 days, 90 days. Method of measurement: HPLC.;Seminal plasma gluthation peroxidase. Timepoint: 45 days, 90 days. Method of measurement: spectrophotometry.
© Copyright 2025. All Rights Reserved by MedPath